Sugi Predict
/ Targets
/ XRCC5
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to XRCC5 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency |
PHASE2/PHASE3 | RECRUITING |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) |
PHASE2 | UNKNOWN |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma |
PHASE1/PHASE2 | COMPLETED |
| A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) |
PHASE2 | COMPLETED |
| Phase II ABT-888 With Cyclophosphamide |
PHASE2 | COMPLETED |
| Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) |
PHASE1/PHASE2 | COMPLETED |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems |
PHASE1 | WITHDRAWN |
| Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome |
nan | UNKNOWN |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| Chromosomal Translocations in Chandigarh Police |
nan | COMPLETED |
| DNA Repair Genes and Outcomes in Patients With Stage III NSCLC |
nan | UNKNOWN |
| Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews |
nan | COMPLETED |
| Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base |
nan | RECRUITING |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma |
nan | COMPLETED |
| Genetics of Prostate Cancer in Young Patients |
nan | COMPLETED |
| Telomere Repair Gene Mutation in Inflammatory Bowel Disease |
nan | COMPLETED |
| DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease |
nan | COMPLETED |
| Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility |
nan | RECRUITING |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a XRCC5 binder may also engage these)